搜索到 1000 条关于 완도녀후기 Ap131.top 빅남자 AV오리 밤사랑 szE 的文章

标准不一,又何谈学术伦理?

2014.03.11 标准不一,又何谈学术伦理?

ligase),可以催化它的 15 个长链氨基酸受体肽(amino acid acceptor peptide, AP)受质中的赖氨酸(Lysine)生物素化(biotinylation)反应。所以,生物素化的 AP 即可和含萤光的共轭链酶亲和素(streptavidin)结合,如此便可观测到活神经细胞表面交互作用的萤光

2012.09.19 2012 中国医疗器械高峰论坛

trials and regulatory affairs
A special showcase of top 10 Chinese innovative device companies and top 5 selected US/EU device companies interested in China

2020.06.17 【直播 | 现场】计算机辅助设计—分子模拟与蛋白互作研讨班(8.20-22)

。【报名回执】访问此链接填写报名回执(https://www.wjx.top/jq/80710449.aspx)【咨询请联系】QQ 号:2814500767邮箱

2012.09.19 2011年生物仿制药会议(Biosimilars Asia 2011)

时间: 2011-5-23 至 2011-5-26
地点:Grand Hyatt Shanghai
主办单位: IBC Asia (S) Pte Ltd

会议简介

According to Business Insights, an estimated $25bn worth of biologics will lose patent protection by 2016, creating a significant market opportunity for biosimilars. However, the reality is that biosimilar development is a risk-fraught activity that demands significant resources in R&D, manufacturing expertise, regulatory know-how, clinical-trial capabilities, and a high level of financial investment.

Biosimilar development is riddled with complexities, ranging from regulatory, to manufacturing to marketing, and is one of the most expensive propositions in the pharmaceutical industry. It is estimated that it costs between US$100-200 million to bring a biosimilar product to market. With so much at stake, biosimilars represent not only substantial growth but equally risk..

IBC’s 2nd Annual Biosimilars Asia 2011 Summit is the ONLY conference in Asia catering to this region’s specific queries. With unprecedented insights from leading innovators and biosimilar companies, you will network and learn how to strategically position your company to maximize your ROI. Biosimilars Asia 2011 is attended by key stakeholders in the region and beyond, enabling you to make informed strategic decisions.

5 Reasons To Attend
  • Only conference in Asia which addresses concerns faced by the Asian biosimilar companies with experts from the region and beyond
  • Learn from and personally meet senior executives from the major stakeholders amongst from biosimilar to innovator companies
  • The most comprehensive event highlighting key challenges in the industry including manufacturing, marketing, pricing, transitioning from generics to biosimilars and regulatory issues
  • Showcasing unique case studies from leading Asian and international biosimilar companies
  • Gather the latest insights from regional biosimilar companies and MNCs about their strategic decisions and how they are positioning themselves for success

Industry Gurus / Speakers
Biocon, Pfizer, Genentech, Roche, Teva, Hospira, Sandoz, Momenta, Intas, Dr Reddy’s, Shenzhen Main Luck Pharmaceuticals

Past Attendees Include
Vice President, ASTRAZENECA INNOVATION CENTER (China)
Senior Director, GENENTECH INC, (USA)
Managing Director, BECTON DICKINSON CO (BD BIOSCIENCES) (Singapore)
Managing Director, ASAHI GLASS CO LTD (Japan)
Deputy General Manager, SINOPHARM (China)
Head, Biotech Research, USV LTD (India)
General Manager, JCR PHARMACEUTICALS CO LTD (Japan)
Vice President, R&D/Business Development, MAIN LUCK PHARMACEUTICALS INC (China)
Senior Research Associate, HANWHA CHEMICAL (South Korea)
Vice President, BOEHRINGER INGELHEIM GMBH (Germany)
General Manager, GLAXOSMITHKLINE (CHINA) INVESTMENT CO LTD (China)
IP Director, HOSPIRA (AUSTRALIA)
President, MYCENAX BIOTECH INC (Taiwan)
Senior Director, MERCK & CO INC (USA)
Associate Director, DR REDDY''''''''S LABORATORIES LTD (India)
Chairman, SHENZHEN SCIPROGEN BIO-PHARMACEUTICAL CO LTD (SCIPROGEN) (China)COO, SHANGHAI CELGEN BIOPHARMACEUTICALS (China)
Chief Representative, TTY BIOPHARM CO LTD (Taiwan)COO, 3SBIO (China)
Project Director, JIANGSU CHIA TAI TIANQING PHARMACEUTICAL CO LTD (China)Associate Director, PFIZER INVESTMENT CO LTD (China)
General Manager, NIPPON KAYAKU CO LTD (Japan)
President, HENLIUS BIOPHARMACEUTICALS INC & SHANGHAI HENLIUS BIOTECH (USA)
Vice President, RANBAXY (USA)

Registration

FEES per delegate
Early Bird Rate
Register & Pay before 11 March 2011
Special Rate
Register & Pay before 15 April 2011
Normal Rate
Register & Pay after 15 April 2011
Group Rate
Group of 3 or more
?
US$ / CNY
US$ / CNY
US$ / CNY
US$ / CNY
4 day package
(Conf + Pre & Post Workshops)
2,495 /
16,600
2,695 /
17,950
2,895 /
19,500
2,175 /
14,650
3.5 day package (Conf + Workshop C & A or B )

2,295 /
15,500

2,495 /
16,600
2,695 /
17,950
2,025 /
13,500
3 day package (Conf + Workshop A & B or C)
1,995 /
13,500
2,195 /
14,600
2,395 /
15,950

1,795 /
12,000

2.5 day package (Conf + Workshop A or B)
1,795 /
12,000
1,995 /
13,500
2,195 /
14,600
1,695 /
10,950
2 day package
(Conf only)
1,495 /
9,950
1,695 /
11,300
1,895 /
12,600
1,495 /
9,950

Register Now

PAYMENT TERMS

Payment must be received 10 business days prior to the event. To take advantage of discounts with an expiry cut-off date, registration and payment must be received by the cut off date.

Payments by Singapore Dollars (S$)

  • Payments by S$ bank draft or cheque should be made in favour of “IBC Asia (S) Pte Ltd” payable in Singapore.
  • Payment by telegraphic transfer in S$ must be made to:
    IBC Asia (S) Pte Ltd
    A/C No.: 147-059513-001 (SGD)
    The Hongkong and Shanghai Banking Corporation Limited
    21 Collyer Quay, HSBC Building, Singapore 049320
    Bank Swift Code: HSBCSGSG
    Bank Code: 7232
  • Payment by Credit Card (AMEX, VISA or MASTERCARD). Please provide your Card Number, Name of Cardholder, Expiry Date and your Signature and send it by fax to +65 6508 2407.
Payments by RMB (CNY)
  • Payment by telegraphic transfer in CNY must be made to:
    A/C Name:
    A/C No.: 720-031103-001
    Beneficiary Bank:
    Bank Address: No. 1000 Lujiazui Rind Road,
    Pudong, Shanghai 200120, P.R. China
    Bank Swift Code: HSBCCNSH
CANCELLATIONS SUBSTITUTION
Should you be unable to attend, a substitute delegate is welcome at no extra charge. Cancellations must be received in writing at least 10 business days before the start of the event, to receive a refund less 10% processing fee per registration. The company regrets that no refund will be made available for cancellation notifications received less than 10 business days before the event.IMPORTANT NOTE:
Please quote the name of the delegate, event title and invoice number on the advice when remitting payment. Bank charges are to be deducted from participating organisations own accounts. Please fax your payment details (copy of remittance advice, cheque or draft to +65 6508 2407.

Attendance will only be permitted upon receipt of full payment. Participants wishing to register at the door are responsible to ensure all details are as published. IBC Asia will not be responsible for any event re-scheduled or cancelled.


DATA PROTECTION
The personal information entered during your registration/order, or provided by you, will be held on a database and may be shared with companies in the Informa Group in the UK and internationally. Sometimes your details may be obtained from or shared with external companies for marketing purposes. If you do not wish your details to be used for this purpose, please contact Winnie Seah (Database) on winnie.seah@ibcasia.com.sg Tel: +65 6508 2468 or Fax: +65 6508 2408.
联系方式电话:+65 650 82401
清醒麻醉下经皮内镜脓肿切除术可有效治疗胰腺脓肿

2014.11.26 清醒麻醉下经皮内镜脓肿切除术可有效治疗胰腺脓肿

急性胰腺炎(acute pancreatitis,AP)可分为间质水肿型及坏死型,其中后者可引起诸多并发症,并存在一定的死亡率,与死亡率相关的因素包括脏器衰竭及胰腺脓肿(infected pancreatic necrosis,IPN)。 AP早期患者主要死于脏器衰竭,称之为重型胰腺炎或爆发性胰腺炎,晚期死亡的主要
卒中后抗血小板出血风险有多大?有这10个特征需谨慎

2017.08.13 卒中后抗血小板出血风险有多大?有这10个特征需谨慎

)(即 S2TOP-BLEED 评分模型,见表1)。表 1 预测严重出血的S2TOP-BLEED 评分(来自多变量 Cox 回归模型)具体评分方法为,根据患者临床特征评估 S2TOP-BLEED 评分列表中每一栏分值,除了年龄相关的项目外,将其他所有项目分值想加得总分,再将总分代入图 1 所示风险分布图中,得到不同
远程协作治疗创伤后应激障碍

2014.12.23 远程协作治疗创伤后应激障碍

明,使用远程医疗工具,如电话,互动视频和共享电子病历进行的多学科PTSD非现场干预,即创伤后应激障碍远程医疗服务(TOP)与常规护理(UC)相比,治疗效果显著提升...包括了2009年11月至2011年9月份在CBOCs接受治疗的265名主要生活在农村的退伍军人。所有患者均符合PTSD诊断标准,他们被随机分配接受TOP治疗(N
高再荣教授专访:难治性甲状腺癌的治疗策略

2017.08.23 高再荣教授专访:难治性甲状腺癌的治疗策略

,包括碘 131 全身扫描、颈部超声、CT 和磁共振等;三是分子标志物的检测。以上都是评价 RAI 治疗效果的重要手段。在评估过程中,必须贯穿一个很重要的理念,即动态评估。因为评价疗效不是一次决定终身,而是应该根据碘 131 治疗的时间和病情变化进行动态分层。丁香园:目前,国际上对于 RAI 抵抗的标准还存在争议,对此
EMA 专家小组建议批准辉瑞乳腺癌药物Ibrance

2016.09.19 EMA 专家小组建议批准辉瑞乳腺癌药物Ibrance

幅上涨。Ibrance 在 2015 年 2 月获得美国食品和药物管理局批准,在最近的一个季度中,为辉瑞公司 131 亿美元的季度销售额贡献了约 5 亿美元
王肖原主任中医师

2016.06.30 王肖原主任中医师

王肖原,主任中医师。杭州市基层名中医,儿科疾病专家。浙江省中医药学会儿科分会常务委员及青年委员会副主任委员、萧山中医药学会理事。萧山跨世纪科技人才培养人选、杭州市新世纪「131」 优秀中青年人才第三层次培养人选、第三批全国优秀中医临床人才。一直在中医儿科临床工作,曾先后师从省级名老中医宣桂琪、国家级名老中医王霞芳
中国与美国甲状腺结节与分化型甲状腺癌诊治指南比较

2014.03.17 中国与美国甲状腺结节与分化型甲状腺癌诊治指南比较

随着甲状腺癌发病率的上升,国内开始重视甲状腺结节及分化型甲状腺癌的治疗,并发布了最新的相关指南,该指南与美国国立综合癌症网络(NCCN)、美国甲状腺学会(ATA)指南相比,在甲状腺结节术前评估、手术方式、术后131I 治疗及促甲状腺激素(TSH)抑制治疗方面均更加贴近我国国情,尤其是增加了良性甲状腺结节的治疗建议
多次复发的甲亢病例一例

2011.10.20 多次复发的甲亢病例一例

手术治疗又颇为忌惮,是否须I131治疗或中医针灸治疗(据说传统医学在治疗甲亢方面有独特的疗效);3:如继续口服药物,方案如何调整?请各位老师、同仁赐教。曾春霞:患者心率、血压、血常规是否正常?如果反复发作,无碘131治疗禁忌症,本人还是会建议碘131治疗,不过一定要跟病人说明会引起甲减的副作用,并且有40

2015.06.04 EMSA 问题与解答

(目录号E3050)包括含重组AP2蛋白(AP2抽提液)的大肠杆菌抽提液和AP2的同源寡核苷酸。AP2抽提液是从表达AP2蛋白的大肠杆菌中提取的。另外,Core...,分别是AP1、OCT1、CREB,、NF-kB、 TFIID结合位点的同源序列。这些寡核苷酸可以在末端标记后用作特异性探针,或在竞争实验中用作非特异性探针。参考
说好的 PLUS 会员来啦!说明书上传 3 月排行榜出炉

2022.04.06 说好的 PLUS 会员来啦!说明书上传 3 月排行榜出炉

到了 825 份说明书,经过后台小助手日以继夜的审核,最终角逐出「3 月说明书上传榜」前三名:Top 1: 楠楠一沐 有效说明书 43 份Top 2: Eric_xzt 有效说明书 20 份Top 3: dxy_00wxf3se
中国的科研用户都在搜什么文献?

2016.04.25 中国的科研用户都在搜什么文献?

这点是无疑的,肿瘤研究是并且也将一直是科研用户最关注的点,那么紧接着就让我们看看中国的科研用户更关注哪些疾病的研究?最关注的疾病类型 TOP10从以上排名来看... (分别为:糖尿病和 HIV),从某一个角度上说明了这两种疾病所受的关注度与肿瘤疾病不相上下。接着从用户检索的关键词中统计出了中国科研用户最关注的基因 TOP
2014年FDA批准新药的销售额预测

2014.07.08 2014年FDA批准新药的销售额预测

重磅炸弹。按照Bloomberg的预测,2013年上市的新药经过5年的市场推广和培育,销售额top10的新药都将迈过10亿美元的门槛,2018年这10个新药的销售额...药物Xtandi同样备受关注,但 5年之后(即2017年)top10的销售总额预计仅为大约150亿美元,可以说完败于2013年。进入2014年, FDA在1~6

2012.05.02 风向变了,Good Bye, SCI

, SCI”还不是一个很容易的事情。无论如何,这仅仅是时间的问题,早晚的事情。数年前(2008年初),大呆曾经写过一个系列的博文《Top Journals 是标准吗》,对SCI这个问题有过比较系统的阐述,现在看来,当时的一些观点并没有过时。特别是,在Top Journals 是标准吗-7和Top

2011.08.15 三维CT重建的计算机模拟技术在伯尔尼髋臼周围截骨术中的应用

龄为14-42岁,平均24岁。术前行髋关节螺旋CT扫描并进行三维重建,使用“Top View”技术及Azuma分级对股骨头覆盖程度进行评估...^o(-10^o-18^o),Top View的股骨头覆盖率平均为63.5%(50%-77%)。术后平均外侧CE角为30.1^o(13^o-47^o),臼顶倾斜角
上一页 1 2 3 ... 39 40 41 ... 48 49 50 下一页 到第